Review Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: Results of a multicentric study P. Ghillani a,b, ⁎, C. André b , C. Toly b , A.M. Rouquette b , D. Bengoufa b , P. Nicaise b , C. Goulvestre b , A. Gleizes b , M.A. Dragon-Durey b , M.A. Alyanakian b , P. Chretien b , S. Chollet-Martin b , L. Musset a,b , B. Weill b , C. Johanet b a Laboratoire d'Immunochimie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France b Groupe Auto-immunité de la Collégiale d'Immunologie, Assistance Publique, Hôpitaux de Paris, France abstract article info Article history: Received 28 February 2011 Accepted 15 March 2011 Available online 5 April 2011 Keywords: Anti-Ro52 (TRIM21) antibodies Autoimmune diseases tRNA antisynthetase syndrome Interstitial lung disease Ro52 antigen has recently been identified as TRIM21 protein, but the clinical significance of anti-Ro52/TRIM21 antibodies remains controversial. The aim of this multicentric study was to investigate the significance of anti- Ro52 antibodies without anti-SSA/Ro60 antibodies in various connective diseases. Sera were selected by each laboratory using its own method (ELISA, immunodot or Luminex technology), and then performed with ANA Screen BioPlex™ reagent (BIO-RAD). Among the 247 screened sera, 155/247 (63%) were confirmed as anti- Ro52 positive and anti-SSA/Ro60 negative. These sera were analyzed for the detection of other antibodies in relation with clinical settings. Isolated anti-Ro52 antibodies were detected in 89/155 (57%) sera. For the remaining sera (66/155), the main antibodies associations were Sm/SmRNP or Chromatin (n = 38; 57%), Jo1 (n = 17; 26%) and CenpB (n = 9; 14%). Clinical data from the 155 patients showed high prevalence in autoimmune diseases (73%) including myositis or dermatomyositis (n = 30), lupus (n = 23); Sjögren and/or sicca syndrome (n = 27); CREST or Systemic sclerosis (n=11) and autoimmune hepatitis (n=11). We found that pulmonary manifestations were often associated with the presence of anti-Ro52 antibodies (n = 34, 22%), in addition with anti-tRNA synthetases, anti-SRP or anti- Ku antibodies (18/34) or isolated in half of cases (16/34). Separate detection of anti-Ro52 antibodies might be useful in related antisynthetase syndrome diagnosis. The presence of anti-Ro52 antibodies should probably precede development of autoimmune disease and must induce sequential follow-up of positive patients, particularly in interstitial lung disease progression. © 2011 Elsevier B.V. All rights reserved. Contents 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509 2. Patients and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 2.1. Inclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 2.2. Antibodies detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 2.3. Definition of isolated anti-Ro52 antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511 5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512 Take-home messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513 1. Introduction Antibodies to SSA antigen (Ro52/Ro60), historically described as a marker for Sjögren syndrome and systemic lupus erythematosus are now known not to be directed to the same macromolecular complex [1]. It is well admitted that Ro52 and Ro60 (SSA) antigens consisted of Autoimmunity Reviews 10 (2011) 509–513 ⁎ Corresponding author at: Laboratoire d'Immunochimie, Groupe Hospitalier Pitié- Salpêtrière, 83 bld de l'Hôpital, 75013 Paris, France. Tel.: + 33 1 42 17 84 98; fax: + 33 1 42 17 84 83. E-mail address: pascale.ghillani-dalbin@psl.aphp.fr (P. Ghillani). 1568-9972/$ – see front matter © 2011 Elsevier B.V. All rights reserved. doi:10.1016/j.autrev.2011.03.004 Contents lists available at ScienceDirect Autoimmunity Reviews journal homepage: www.elsevier.com/locate/autrev